How Should You Measure Your Research Impact?

December 16, 2014

(2012) Altmetrics Collection. 2(19): ev02.i19. doi:10.1371/image.pcol.v02.i19


Publishers, funders, promotion committees and researchers use metrics–like impact factor or h-index–to assess how pivotal research was in a given community. Impact factor and h-index focus on how many people cite a particular paper after publication. In a nutshell, the more the paper is cited, the more impact it has.

Critics point out several issues with traditional metrics:

  • How do you account for journal/author self-citations?
  • How can citation counts measure whether a paper was well-received or criticized?
  • How can we measure impact of research data, not just the impact of a published paper?
  • How does publishing in open access journals affect impact metrics?
  • How can you measure whether research is ‘trending‘ or creates immediate impact–after all, the peer-review and publication process takes time?

New measurements, called altmetrics, attempt to solve these issues.

To learn more or contribute to the conversation, check out the National Information Standards Organization’s Initiative to establish new standards and tools to assess research impact.

To learn more about the development of altmetrics, check out the PLOS Altmetrics collection and CW Bailey’s bibliography.

To see current conversations, check out Mendeley’s #altmetrics group.

New Permissions Allow Nature Article Sharing

December 12, 2014


Nature announced this month a new content-sharing policy. The policy allows all research papers within the publication to be shared by subscribers to anyone via a screen-view format. Through National Jewish Health’s institutional subscription, users can access and share any paper the journal has published from 1997 onward. The sharing platform, ReadCube, generates a persistent link to an article that allows the shared article to be read, but not printed or downloaded. There is an annotation tool that allows collaboration between researchers and there are additional tools available if users wish to download the ReadCube app. You can view an example of what a shared article would look like via this link:, which was generated through Nature’s new share feature.

More information is available here.

Lexi-Comp Mobile

November 26, 2014

Did you know we own Lexi-Comp?
It will look familiar to you because UpToDate uses a limited version of Lexi-Comp for drug content.

Get mobile access (set up from campus):

  • Lexi-Drugswith AHFS Essentials & AHFS DI, and Lexi-Drugs International
  • Pediatric & Neonatal and Geriatric Lexi-Drugs
  • Extensive medical calculations
  • Natural Products
  • Pharmacogenomics
  • Lab and Diagnostic Procedures
  • Drug, drug allergy, herbal interaction and duplicate therapy analysis
  • Identification of drugs in various dosage forms
  • V. compatibility via King Guide to Parenteral Admixtures and Trissel’s IV Chek
  • Assessment, diagnosis, and treatment of poisonings and drug overdoses
  • Facts & Comparisons for comparative data tables
  • Infectious Diseases:
    This all-inclusive database assists in the diagnosis and treatment of infectious diseases, combining disease syndromes, organisms, diagnostic tests, and antimicrobial therapy into one easy-to-use reference. Monographs for bioterrorism are included.
  • Patient education:
    Leaflets providing drug, disease, condition and procedure, discharge instructions, natural product, and healthy living information for your patients – all available in Spanish. In addition, over 340 of the most frequently accessed leaflets are also available in 19 languages.

New and Enchanced Lexicomp Online Features

August 6, 2014

Lexicomp enhancements

Lexicomp Online has enhanced and added several new features to help make the database usability more streamlined.

  • Comparative efficacy data is now accessible through a direct link within the core drug monographs. Previously, a separate search was necessary, so this should help ease workflow when researching.
  • Wolters Kluwer Clinical Drug Information has partnered with the Society of Critical Care Medicine (SCCM) and its Drug Shortages Task Force to supplement Lexicomp drug shortage information. Monographs for drugs with current shortage issues will now include links to SCCM’s recommendations for alternatives.
  • Lexicomp has expanded its Medical Calculator module, adding over 40 new calculators developed per customer requests. Some of the new calculators include Glomerular Filtration Rate Estimate and Benzodiazepine Dosing Conversion. There are now over 130 calculators available through Lexicomp.

NJH patrons can access Lexicomp Online through the library’s homepage and see additional notes on these and other new features.

USPSTF A-Z Topic Guide

August 4, 2014

USPSTF banner

The U.S. Preventive Services Task Force (USPSTF) has released a list of all preventative measure recommendations, including screenings, counseling, immunizations, and preventative measures. The comprehensive list can be viewed alphabetically by topic and includes all active, inactive, and in progress recommendations for children, adolescents, and adults. The full list can be viewed on their website at

Have you Recently Contributed to a Book?

May 30, 2014

National Jewish Health faculty and staff: If you’ve recently contributed to professional books, please let us know so we can add a copy to our collection. All donations and suggested titles are welcome.

Email Peggy with suggestions and keep up the hard work!

Incoming ATS President Stresses Importance of Clinical Scientists

May 16, 2014

At National Jewish Health, clinicians and researchers work together to discover innovative therapies to improve patient health. Our focus on personalized medicine and translational research is in line with incoming ATS President, Dr. Thomas Ferkol’s initiative to involve more “clinical scientists” in respiratory medicine.

MedPage today interviews Dr. Ferkol about this initiative.

“One of the difficulties that we’re seeing — we certainly see this in pediatric pulmonology and I’m afraid that we are a harbinger of things to come — is that there are fewer and fewer people who are going into the field and becoming physician scientists or clinical investigators,” he explained in an interview.

Now with technology to understand complex networks of genes, gene products, and environmental factors that influence lung health and disease “we are truly entering an era where we can unlock the mysteries of lung disease,” he told MedPage Today.

But “in order to really make this happen, we need to have pulmonary scientists and clinical investigators who can bring these discoveries from the bench to the bedside,” he said.

Read the full story.

Read about NJH’s research initiatives.

Thomas Ferkol, Jr., MD

Thomas Ferkol, Jr., MD


Get every new post delivered to your Inbox.

Join 27 other followers